WO2024240173 - AN ANTIBODY-DRUG CONJUGATE HAVING TWO OR MORE FUNCTIONAL SMALL MOLECULE COMPOUNDS FOR ENHANCED TREATMENT OF REFRACTORY DISEASES
National phase entry:
Publication Number
WO/2024/240173
Publication Date
28.11.2024
International Application No.
PCT/CN2024/094651
International Filing Date
22.05.2024
Title **
[English]
AN ANTIBODY-DRUG CONJUGATE HAVING TWO OR MORE FUNCTIONAL SMALL MOLECULE COMPOUNDS FOR ENHANCED TREATMENT OF REFRACTORY DISEASES
[French]
CONJUGUÉ ANTICORPS-MÉDICAMENT AYANT AU MOINS DEUX COMPOSÉS À PETITES MOLÉCULES FONCTIONNELS POUR LE TRAITEMENT AMÉLIORÉ DE MALADIES RÉFRACTAIRES
Applicants **
HANGZHOU SEEHE BIOTECHNOLOGY CO., LTD
Building 19, ZhengTaiZhongZi Tech. Park, No. 260 Sixth Street, HEDA,
Hangzhou, Zhejiang 310018, CN
ZHAO, Robert Yongxin
7 Loring Road, Lexington, Massachusetts 02421, United States Of America
Massachusetts, US
HANGZHOU DAC BIOTECH CO., LTD
Building 12, ZhengTaiZhongZi Tech. Park, No. 260 Sixth Street, HEDA,
Hangzhou, Zhejiang 310018, CN
Inventors
YANG, Qingliang
Building 12, ZhengTaiZhongZi Tech. Park, No. 260 Sixth Street, HEDA,
Hangzhou, Zhejiang 310018, CN
HUANG, Yuanyuan
Building 12, ZhengTaiZhongZi Tech. Park, No. 260 Sixth Street, HEDA,
Hangzhou, Zhejiang 310018, CN
YE, Hangbo
Building 12, ZhengTaiZhongZi Tech. Park, No. 260 Sixth Street, HEDA,
Hangzhou, Zhejiang 310018, CN
ZHANG, Lingli
Building 12, ZhengTaiZhongZi Tech. Park, No. 260 Sixth Street, HEDA,
Hangzhou, Zhejiang 310018, CN
GUO, Huihui
Building 12, ZhengTaiZhongZi Tech. Park, No. 260 Sixth Street, HEDA,
Hangzhou, Zhejiang 310018, CN
JIA, Junxiang
Building 12, ZhengTaiZhongZi Tech. Park, No. 260 Sixth Street, HEDA,
Hangzhou, Zhejiang 310018, CN
BAI, Lu
Building 12, ZhengTaiZhongZi Tech. Park, No. 260 Sixth Street, HEDA,
Hangzhou, Zhejiang 310018, CN
WANG, Juan
Building 12, ZhengTaiZhongZi Tech. Park, No. 260 Sixth Street, HEDA,
Hangzhou, Zhejiang 310018, CN
LI, Wenjun
Building 12, ZhengTaiZhongZi Tech. Park, No. 260 Sixth Street,
Hangzhou, Zhejiang 310018, CN
Priority Data
PCT/CN2023/096066
24.05.2023
CN
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| * | |
International Searching Authority |
CNIPA
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Translation |
|
Recalculate
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing | 13784 | |
| EPO | Filing, Examination | 28021 | |
| Japan | Filing | 587 | |
| South Korea | Filing | 574 | |
| USA | Filing, Examination | 11510 |
Total: 54476 USD
The term for entry into the National Phase has expired. This quotation is for informational purposes only
Abstract[English]
An antibody-drug conjugate containing a side chain of a functional small molecule for enhancement of targeted treatment of cancers and refractory diseases is provided. The preparation of such conjugate, pharmaceutical compositions, and methods in treatment of refractory diseases are also provided.[French]
L'invention concerne un conjugué anticorps-médicament contenant une chaîne latérale d'une petite molécule fonctionnelle pour l'amélioration du traitement ciblé de cancers et de maladies réfractaires. L'invention concerne également la préparation d'un tel conjugué, des compositions pharmaceutiques et des méthodes de traitement de maladies réfractaires.